Related content

Approaches to the discovery of pharmacogenomic markers in oncology: 2000–2010–2020

By Huang R Stephanie   Dolan M Eileen  

Pharmacogenomics, Vol. 11, Iss. 4, 2010-04 ,pp. : 471-474

Future Medicine

Access to resources Recommend Favorite

Application of the F_ST statistics to explore pharmacogenomic diversity in the Brazilian population

By Suarez-Kurtz Guilherme   Pena Sergio DJ   Hutz Mara H  

Pharmacogenomics, Vol. 13, Iss. 7, 2012-05 ,pp. : 771-777

Future Medicine

Access to resources Recommend Favorite

Allele and genotype frequencies of polymorphic , , , and in the Egyptian population

By Hamdy Samar   Hiratsuka Masahiro   Narahara Kaori   El-Enany Mervat   Moursi Nadia   Ahmed Mohammed   Mizugaki Michinao  

European Journal of Clinical Pharmacology, Vol. 58, Iss. 1, 2002-04 ,pp. : 29-36

Springer Publishing Company

Access to resources Recommend Favorite

Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records

By Oetjens Matthew T   Denny Joshua C   Ritchie Marylyn D   Gillani Niloufar B   Richardson Danielle M   Restrepo Nicole A   Pulley Jill M   Dilks Holli H   Basford Melissa A   Bowton Erica   Masys Dan R   Wilke Russell A   Roden Dan M   Crawford Dana C  

Pharmacogenomics, Vol. 14, Iss. 7, 2013-05 ,pp. : 735-744

Future Medicine

Access to resources Recommend Favorite

Allelic combinations of immune-response genes as possible composite markers of IFN-&bgr; efficacy in multiple sclerosis patients

By Kulakova Olga G   Tsareva Ekaterina Yu   Boyko Alexey N   Shchur Sergey G   Gusev Evgeny I   Lvovs Dmitrijs   Favorov Alexander V   Vandenbroeck Koen   Favorova Olga O  

Pharmacogenomics, Vol. 13, Iss. 15, 2012-11 ,pp. : 1689-1700

Future Medicine

Access to resources Recommend Favorite